Biolase
BIOL
BIOL was delisted on the 18th of June, 2024.
36 hedge funds and large institutions have $30.7M invested in Biolase in 2016 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 1 closing their positions.
600% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 1
384% more capital inflows, than outflows
Capital inflows: $301K | Capital outflows: $62.2K
20% more funds holding
Funds holding: 30 → 36 (+6)
0.37% more ownership
Funds ownership: 39.82% → 40.18% (+0.37%)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Consonance Capital Management
New York
|
+$150K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$37.6K |
| 3 |
Virtu KCG Holdings
New York
|
+$37.6K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$25.1K |
| 5 |
Guggenheim Capital
Chicago,
Illinois
|
+$12.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCMI
Princeton Capital Management Inc
Princeton,
New Jersey
|
-$37.6K |
| 2 |
BlackRock Fund Advisors
San Francisco,
California
|
-$12.5K |
| 3 |
IFP Advisors
Tampa,
Florida
|
-$11K |
| 4 |
American International Group
New York
|
-$1K |
BIOL Hedge Fund Activity: Q1 2016 in Review
36 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Biolase (BIOL) for Q1 2016, worth a combined $30.7M — up 57% from $19.5M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new BIOL positions and 1 closed out — a net gain of 6 holders — while 1 added to existing stakes and 2 trimmed.
The largest buyer was Consonance Capital Management, adding an estimated $150K. The largest seller was Princeton Capital Management Inc, cutting an estimated $37.6K.
- 36 institutional investors held Biolase (BIOL) as of Q1 2016, up from 30 in Q4 2015.
- Funds reported $30.7M of Biolase stock for Q1 2016, up 57% quarter-over-quarter.
- 7 funds opened new Biolase positions in Q1 2016 and 1 closed out, a net change of +6 holders.
- The largest Biolase buyer in Q1 2016 was Consonance Capital Management, an estimated $150K added.
- The largest Biolase seller in Q1 2016 was Princeton Capital Management Inc, an estimated $37.6K sold.
Based on aggregated 13F filings for Q1 2016.